Clinical Trial: NCT05673187
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | ETOP IBCSG Partners Foundation |
| Information Provided By: | ETOP IBCSG Partners Foundation |
| Last Update Posted: | 2026-09-03 |
Study Overview
Brief Summary
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The primary objective of this trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response, in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status (ECOG PS=2).
Official Title
Conditions
Intervention / Treatment
- Drug: Adagrasib
Other Study ID Numbers
- ETOP 22-22
- 2022-002736-31
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | ETOP IBCSG Partners Foundation |
| Information Provided By: | ETOP IBCSG Partners Foundation |
| Last Update Posted: | 2026-09-03 |
Study Overview
Brief Summary
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The primary objective of this trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response, in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status (ECOG PS=2).
Official Title
Conditions
Intervention / Treatment
- Drug: Adagrasib
Other Study ID Numbers
- ETOP 22-22
- 2022-002736-31